Blankning Aktier Ökning / Minskning Top 40 : Vecka 6 2026 omxprat.forumotion.eu/t2790-blankn...

Stor ökning av blankning: #Billerud, #Hemnet, #Embracer, #Elekta, #Alleima.
Stor minskning har vi i: #Elux, #Sdiptech, #SKF, #EVO, #Tele2
Se listorna för mer fakta:

Blankning Aktier Ökning / Minskning Top 40 (5 & 10 dagar) : V6 2026

#finanstwitter #hemnet #elekta
För mer tabeller:
omxprat.forumotion.eu/t2790-blankn...

#elekta blir spännande imorgon. Ny VD och en massa skit utrensat i förra rapporten.

Säkert osmart att vara på köpsidan så här tidigt i den här tillnyktringen(?) men även plockat in #Elekta på 43 kr. FDA-godkännande kommer väl snart. Frågan är om ny ledning ska göra en kitchen sink-rapport som första eller om det redan är gjort med vårens nedskrivna ordrar?

Detta får man väl ändå kalla för conviction? #elekta

UBS initiates Elekta at “sell,” cites slowing radiotherapy market and 30% downside Investing.com -- UBS has initiated coverage of Elekta AB (ST:EKTAb) with a “sell” rating, pointing to a weakening outlook for the radiotherapy market and limited prospects for the company’s new platform. The analysts set a 12-month price target of SEK34, about 30% below the September 2 closing price of SEK45.94. Elekta, the world’s second-largest manufacturer of radiotherapy devices, has steadily lost market share to rival Varian over the past decade. Management has positioned its new system, Evo, as a potential turning point. But UBS said, “we remain cautious … Evo is unlikely to move the dial in more than 50% of the global radiotherapy market, where its key USP of enabling adaptive radiotherapy will struggle to find widespread adoption.” The brokerage pointed to slowing market growth in developed economies, driven by fewer new cancer cases, a declining share of patients receiving radiotherapy, and shorter treatment courses. “Developed markets face mounting volume headwinds that lower device utilisation and slow turnover for manufacturers, while growth in emerging markets risks disruption from Chinese players,” UBS said. UBS projects global radiotherapy market growth of 3% to 4% in the medium term, about half of Elekta’s 6% to 8% forecast. The brokerage said consensus expectations are too high, adding, “Although sellside consensus implies market forecasts that are below the company’s guidance, we still believe they are too high.” On valuation, UBS noted that Elekta trades at a significant premium to peers despite weaker free cash flow conversion. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. “Optically cheap, actually expensive,” the brokerage said, concluding that the shares do not reflect the “deep structural risks” to the company’s operating model. The next catalyst for investors will be the company’s second-quarter earnings on November 26, where UBS estimates operating profit could fall 6% short of consensus expectations. The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for EKTABs plus thousands of other stocks and find your next hidden gem with massive upside.

Click Subscribe #Elekta #UBS #StockMarket #Investing #Radiotherapy

Vill någon i #finanssverige ge mig sin take på #Elekta
Låter ju på ”halvnya” ledningen och snart också nya ledningen att bruttomarginalen kommer stärkas härifrån. Kursen nästan på aprilbotten i väntan på rapport. Vad missar jag?

Elekta: Radiotherapy Giant - OncoDaily Elekta is a leading global medical technology company focused on addressing cancer. Based in Sweden, the company develops and provides a c

Elekta: Radiotherapy Giant
@elekta.com

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Elekta #Radiotherapy #Giant #RadiationOncology

Ben Li on Why Hypofractionation Is Important in Low-Resource Settings - Elekta Foundation - OncoDaily Ben Li on Why Hypofractionation Is Important in Low-Resource Settings - Elekta Foundation / Benjamin Li, Breast Cancer, cancer, CNS cancers, Elekta

Ben Li on Why Hypofractionation Is Important in Low-Resource Settings – Elekta Foundation

@elekta.com

oncodaily.com/blog/hypofra...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Elekta #Hypofractionation #Radiology

Habib Nehmé: The U.S. Market Remains Elekta’s Most Strategic and Significant One - OncoDaily Habib Nehmé: The U.S. Market Remains Elekta’s Most Strategic and Significant One / Adrianus Ermers, cancer, Elekta, Habib Nehmé, Javier Pastor, OncoDaily,

The U.S. Market Remains Elekta’s Most Strategic and Significant One - Habib Nehmé
@elekta.com

oncodaily.com/blog/habib-n...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Elekta #USA

Elekta Partners with Gray to Streamline Oncology Appointment Scheduling for Enhanced Patient Care Elekta collaborates with Gray to offer an advanced scheduling platform for oncology services, enhancing operational efficiency and patient experience.

Elekta Partners with Gray to Streamline Oncology Appointment Scheduling for Enhanced Patient Care #Canada #Montreal #oncology #Elekta #GrayOS

Fuse Oncology Partners with Elekta to Enhance Radiation Oncology Clinics Across the U.S. Discover how Fuse Oncology is teaming up with Elekta to revolutionize radiation oncology clinics by improving revenue and compliance with innovative software solutions.

Fuse Oncology Partners with Elekta to Enhance Radiation Oncology Clinics Across the U.S. #United_States #Fuse_Oncology #Boone #Elekta #S!GNAL

#novo, #evo, #elekta

Ny vd igår. Nu början tvätten inför tillträde efter sommaren? #elekta

Kul att #Elekta levererar. Ett av mina större innehav. Fler som äger?

#finanstwitter

Många sänkta riktkurser för #elekta. Har dom kört en runda massage eller är det bara slumpen 🤔
#ektab

19th MR-Linac Consortium meeting expands MRgRT horizons | Focus | Elekta Enthusiasm for MRgRT continues to sweep the globe, as new uses arise clinical evidence pours in. Read about some of the key moments from the 19th Consortium meeting.

🌟New Focus Article Alert 🌟Elekta’s latest Focus article showcases the outstanding contributions of the MRL Consortium members and provides an update on the recent meeting held in Singapore. Read article here: www.elekta.com/focus/mr-lin...
#Elekta #MRLConsortium #HealthcareInnovation #MRgRT